TIDMMPH

RNS Number : 7478D

Mereo BioPharma Group plc

28 April 2017

 
 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 
---------------------------------------------------------------------------------------- 
 
 1. Identity of the issuer or                                  Mereo BioPharma Group plc 
  the underlying issuer 
  of existing shares to which 
  voting rights are 
  attached: (ii) 
-----------------------------------------------------------  --------------------------- 
 2 Reason for the notification (please tick the appropriate 
  box or boxes): 
---------------------------------------------------------------------------------------- 
 An acquisition or disposal of voting rights                               X 
------------------------------------------------------------  -------------------------- 
 An acquisition or disposal of qualifying financial 
  instruments which may result in the acquisition 
  of shares already issued to which voting rights 
  are attached 
------------------------------------------------------------  -------------------------- 
 An acquisition or disposal of instruments with 
  similar economic effect to qualifying financial 
  instruments 
------------------------------------------------------------  -------------------------- 
 An event changing the breakdown of voting rights 
------------------------------------------------------------  -------------------------- 
 Other (please 
  specify): 
----------------------------------------------------------    -------------------------- 
 3. Full name of person(s)                                            Novartis Pharma AG 
  subject to the 
  notification obligation: 
  (iii) 
-----------------------------------------------------------  --------------------------- 
 4. Full name of shareholder(s) 
  (if different from 3.):(iv) 
-----------------------------------------------------------  --------------------------- 
 5. Date of the transaction                                                27 April 2017 
  and date on 
  which the threshold is 
  crossed or 
  reached: (v) 
-----------------------------------------------------------  --------------------------- 
 6. Date on which issuer                                                   27 April 2017 
  notified: 
-----------------------------------------------------------  --------------------------- 
 7. Threshold(s) that is/are 
  crossed or 
  reached: (vi, vii)                                                                 19% 
-----------------------------------------------------------  --------------------------- 
 
 
 
 8. Notified details: 
---------------------------------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares (viii, ix) 
---------------------------------------------------------------------------------------------------------------------- 
 Class/type     Situation previous                   Resulting situation after the 
  of             to the triggering                    triggering transaction 
  shares         transaction 
 
  if possible 
  using 
  the ISIN 
  CODE 
-------------  -----------------------------------  ------------------------------------------------------------------ 
                Number            Number             Number          Number of                % of voting 
                 of                of                 of shares       voting                   rights (x) 
                 Shares            Voting                             rights 
                                   Rights 
-------------  ----------------  -----------------  --------------  -----------------------  ------------------------- 
                                                     Direct          Direct     Indirect      Direct        Indirect 
                                                                     (xi)        (xii) 
-------------      ------------    -------------    --------------  ---------  ------------  ------------  ----------- 
 Ordinary 
 shares 
 of GBP0.03 
 each 
 
 GB00BZ4G2K23   12,546,480        18.1%              13,767,841                               19.5% 
               ----------------  -----------------  --------------  ---------  ------------  ------------  ----------- 
 
 
 B: Qualifying Financial Instruments 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of            Expiration      Exercise/                          Number of voting           % of voting 
 financial           date            Conversion                         rights that                rights 
 instrument          (xiii)          Period (xiv)                       may be 
                                                                        acquired if 
                                                                        the 
                                                                        instrument 
                                                                        is 
                                                                        exercised/ 
                                                                        converted. 
-----------------  --------------  ---------------------------------  -------------------------  --------------------- 
 
 
 C: Financial Instruments with similar economic effect 
  to Qualifying Financial Instruments (xv, xvi) 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of          Exercise        Expiration       Exercise/         Number of voting           % of voting 
 financial         price          date             Conversion         rights instrument          rights (xix, 
 instrument                       (xvii)           period             refers to                  xx) 
                                                   (xviii) 
---------------  --------------  ---------------  ----------------  -------------------------  ----------------------- 
                                                                                                Nominal       Delta 
---------------  --------------  ---------------  ----------------  -------------------------  ------------  --------- 
 
 
 Total (A+B+C) 
---------------------------------------------------------------------------------------------------------------------- 
 Number of voting rights                               Percentage of voting rights 
----------------------------------------------------  ---------------------------------------------------------------- 
 13,767,841                                            19.5% 
----------------------------------------------------  ---------------------------------------------------------------- 
 
 
 
 9. Chain of controlled undertakings through which the 
  voting rights and/or the 
  financial instruments are effectively held, if applicable: 
  (xxi) 
--------------------------------------------------------------------------------- 
 
 
 Proxy Voting: 
--------------------------------------------------------------------------------- 
 10. Name of the proxy holder: 
-------------------------------------------------------------  ------------------ 
 11. Number of voting rights proxy 
  holder will cease to hold: 
-------------------------------------------------------------  ------------------ 
 12. Date on which proxy holder will 
  cease to hold voting rights: 
-------------------------------------------------------------  ------------------ 
 
 
  13. Additional information: 
-------------------------------------------------------------  ------------------ 
 14. Contact name:                                                 Marc Ceulemans 
-------------------------------------------------------------  ------------------ 
 15. Contact telephone number:                                  00 41 61 324 5365 
-------------------------------------------------------------  ------------------ 
 
 
 
 Note: Annex should only be submitted to the FCA not 
  the issuer 
 Annex: Notification of major interests in share 
 
 A: Identity of the persons or legal entity subject to 
  the notification obligation 
-------------------------------------------------------- 
 Full name 
  (including legal form of 
  legal entities) 
------------------------------------------------------ 
 Contact address 
  (registered office for legal 
  entities) 
------------------------------------------------------ 
 Phone number & email 
------------------------------------------------------ 
 Other useful information 
  (at least legal representative 
  for legal persons) 
------------------------------------------------------ 
 
 B: Identity of the notifier, if applicable 
-------------------------------------------------------- 
 Full name 
------------------------------------------------------ 
 Contact address 
------------------------------------------------------ 
 Phone number & email 
------------------------------------------------------ 
 Other useful information 
  (e.g. functional relationship 
  with the person or legal 
  entity subject to the notification 
  obligation) 
------------------------------------------------------ 
 
 C: Additional information 
-------------------------------------------------------- 
 
 For notes on how to complete form TR-1 please see the 
  FCA website.

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLIPMITMBJTBIR

(END) Dow Jones Newswires

April 28, 2017 10:37 ET (14:37 GMT)

Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Mereo Biopharma Charts.
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Mereo Biopharma Charts.